Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 11 -20 of 214 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/9/2008 First Published: 10/1/1996


11.		Phase III Randomized Study of Radiotherapy With or Without Adjuvant Procarbazine, Lomustine, and Vincristine (PCV) in Patients With Resected Highly Anaplastic Oligodendroglioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 to 69								EORTC-26951 MRC-BR11, NCT00002840

Last Modified: 3/25/2008 First Published: 4/1/1997


12.		Phase III Randomized Study of Carboplatin and Vincristine Versus Thioguanine, Procarbazine, Lomustine, and Vincristine in Children With Progressive Low Grade Astrocytoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Under 10				NCI				COG-A9952 CCG-A9952, POG-A9952, CCG-9952, A9952, NCT00002944

Last Modified: 5/17/2007 First Published: 6/1/1998


13.		Phase III Randomized Study of Leflunomide (SU101) Versus Procarbazine for Patients with Glioblastoma Multiforme in First Relapse (Summary Last Modified 01/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				SUGEN-SU101.015 MSKCC-98020, UCLA-HSPC-980105201, NCT00003293

Last Modified: 5/21/2007 First Published: 9/1/1998


14.		Phase III Randomized Study of a Four-Drug Anthracycline-Based Regimen or a Seven-Drug Hybrid or Eight-Drug Alternating Regimen in Patients With Advanced Hodgkin's Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified								MRC-UKLG-LY09 EU-98020, NCT00003421

Last Modified: 5/21/2007 First Published: 10/1/1998


15.		Phase III Randomized Study of Procarbazine With or Without Isotretinoin in Patients with Recurrent Primary Malignant Gliomas (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 and over				NCI				MDA-DM-97050 NCI-T97-0078, NCT00003564, T97-0078

Last Modified: 10/2/2003 First Published: 4/1/1999


16.		Phase III Randomized Study of Photodynamic Therapy Using Porfimer Sodium (Photofrin) in Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other				HEALTHONE-43892 HEALTHONE-1A, HEALTHONE-CA43892, RPCI-DS-9802, NCI-V99-1525, NCT00003788


17.		Phase III Chemotherapy with MOPP (NM/VCR/PCB/PRED) vs OPP (VCR/PCB/PRED) for Recurrent Brain Tumors in Children (Summary last modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and under				NCI				POG-7621

Last Modified: 2/2/2007


18.		Phase III Chemotherapy with BCNU & PCB and Corticosteroids After Surgery and Radiotherapy for Malignant Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				no age specified								BTSG-7501

Last Modified: 2/2/2007


19.		Postoperative Radiotherapy and Combination Chemotherapy with BCNU, PCB, HU, and VM-26 for Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				over 15								BTSG-8001

Last Modified: 7/19/2007


20.		Phase III Chemotherapy with BCNU/CTX/VBL/PCB/PRED Followed by NM/VCR/PCB/PRED for Hodgkin's Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				no age specified								SEG-340

Select All on One Page


					< Previous 1 2 3 4 5 Next >

| | | | | | | |

A Service of the National Cancer Institute